Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HMPL-689 |
| Synonyms | |
| Therapy Description |
HMPL-689 is a specific inhibitor of PIK3CD, which blocks downstream signaling and B-cell activation, potentially resulting in increased anti-tumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr 5454). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HMPL-689 | HMPL689|HMPL 689|Amdizalisib | PIK3CD inhibitor 27 | HMPL-689 is a specific inhibitor of PIK3CD, which blocks downstream signaling and B-cell activation, potentially resulting in increased anti-tumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr 5454). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03786926 | Phase Ib/II | HMPL-689 | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | Terminated | USA | POL | ITA | FRA | FIN | ESP | 0 |